Related content

Comment on: Evans JM, Ogston SA, Emslie-Smith A, Morris A (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936

By Johnson J.   Simpson S.   Eurich D.   Majumdar S.  

Diabetologia, Vol. 49, Iss. 11, 2006-11 ,pp. : 2805-2806

Springer Publishing Company

Access to resources Recommend Favorite

Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936

By Tayek J.  

Diabetologia, Vol. 49, Iss. 11, 2006-11 ,pp. : 2807-2808

Springer Publishing Company

Access to resources Recommend Favorite

Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936

By Raccah D.  

Diabetologia, Vol. 50, Iss. 5, 2007-05 ,pp. : 1109-1110

Springer Publishing Company

Access to resources Recommend Favorite

Response to comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulphonylureas and metformin. Diabetologia 49:930–936

By Evans J.   Morris A.  

Diabetologia, Vol. 50, Iss. 5, 2007-05 ,pp. : 1111-1111

Springer Publishing Company

Access to resources Recommend Favorite

Swiss Hypertension and Risk Factor Program (SHARP): Cardiovascular risk factors management in patients with type 2 diabetes in Switzerland

By Pechère Antoinette   Greminger Peter   Hess Lorenzo   Philippe Jacques   Ferrari Paolo  

Blood Pressure, Vol. 14, Iss. 6, 2005-12 ,pp. : 337-344

Informa Healthcare

Access to resources Recommend Favorite